Profile for European Patent Office Patent: 2805720
✉ Email this page to a colleague
| Country | SPC | SPC Expiration |
|---|---|---|
| Netherlands | 301273 | ⤷ Start Trial |
| Denmark | CA 2024 00018 | ⤷ Start Trial |
| Lithuania | PA2024518 | ⤷ Start Trial |
| Luxembourg | LUC00349 | ⤷ Start Trial |
| Belgium | 2024C/521 | ⤷ Start Trial |
| Austria | 21/2024 | ⤷ Start Trial |
| Denmark | CR 2024 00018 | ⤷ Start Trial |
US Patent Family Members and Approved Drugs for European Patent Office Patent: 2805720
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| 10,857,161 | May 28, 2029 | Catalyst Pharms | AGAMREE | vamorolone |
| 11,833,159 | May 28, 2029 | Catalyst Pharms | AGAMREE | vamorolone |
| 8,334,279 | May 28, 2029 | Catalyst Pharms | AGAMREE | vamorolone |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
